RT Journal Article
SR Electronic
T1 Transmission potential of human monkeypox in mass gatherings
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.06.21.22276684
DO 10.1101/2022.06.21.22276684
A1 Sypsa, Vana
A1 Mameletzis, Ioannis
A1 Tsiodras, Sotirios
YR 2022
UL http://medrxiv.org/content/early/2022/06/21/2022.06.21.22276684.abstract
AB Since May 2022, a large number of monkeypox cases has been reported in non-endemic settings. Taking into account the strict measures implemented due to the COVID-19 pandemic and the desire of people to reclaim what is perceived as lost time, it is anticipated that mass gatherings this summer will be highly attended. Based on data for the secondary attack rate among unvaccinated contacts from endemic countries, we estimate that, on average, more than one secondary case is anticipated per infectious person if he/she has a high number of group contacts (>30) or more than eight close contacts. Although the role of group contacts in mass gatherings is uncertain (less likely to involve physical contact, shorter duration), close contacts associated with the event (e.g. intimate/sexual contact with other attendees) might be the amplifying event. Enforcing awareness, early recognition and engaging affected populations in the monkeypox response are important to control transmission.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNot applicable (simulations using estimates from the literature)